AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom
The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement.
It will also upgrade the Anglo-Swedish drugmaker's U.S. clinical trial supply network and support ongoing investment in novel medicines.
On Monday, AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from the U.S.
The U.S. accounted for more than 40% of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market — the world's largest, worth $635 billion — before Trump's return to office.
The move to scale up its U.S. footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes.
Trump has called on pharma companies to make more of the medicines they sell in the U.S. within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the U.S. to fall to what other countries pay.
CEO Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and 'equalize' with other countries effectively contributing more to research and development costs. 'The United States cannot build or carry the cost of R&D for the entire world,' he said.
U.S. Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs.
'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness,' said Lutnick in a statement issued by AstraZeneca.
While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to 'get their act together' before any levies take effect.
The company said that the timing and location of the announcement was linked to the U.S. policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place.
The pledge is in addition to the $3.5 billion in investments the company announced in November 2024, the statement said.
PLEDGES
The $50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson, Novartis, and Sanofi.
Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies.
The new Virginia facility — the company's largest single manufacturing investment — will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said.
The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the U.S. and has a global workforce of about 90,000.
In January it scrapped plans to invest 450 million pounds ($607.1 million) in its vaccine manufacturing plant in northern England, citing a cut in government support.
Earlier this month, The Times reported the company was considering moving its stock market listing from London, where it is the exchange's most valuable company worth 159 billion pounds, to the U.S. The company declined to comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
a minute ago
- CNBC
CNBC Daily Open: Japan markets rally on the country's 15% tariff rate — it's a new era of trade
The anchoring effect is one of the sneakiest tools companies use to make us spend money. Here's how it works. Let's say we're shopping for a smartphone manufactured by Dapple, which has just released two new models: a $1,200 model with a big screen and a $900 one that is more compact. The more expensive smartphone will serve as the "anchor" by which we make comparisons, so the $900 model will appear to be value for money — even if it is costly in absolute terms. But we're likely to feel good about choosing it because we've "saved" $300 on our purchase. This scenario seems to be what's happening with the U.S-Japan trade agreement freshly announced late Tuesday stateside. U.S. President Donald Trump said Washington would gain access to Japan's markets for rice and cars — which had been sticking points during negotiations — while the latter would pay 15% tariffs on its exports to America. At first glance, that doesn't sound too positive for Japan. But investors celebrated the news — the Nikkei 225 jumped 3.8% at 1:45 a.m. ET. After all, a 15% tariff rate is a big improvement from the 25% tariff Trump slapped on Tokyo earlier this month. Furthermore, Japanese auto exports to the U.S. — which made up 28.3% of all shipments in 2024 — will face a tariff of 15%, lower than the universal 25% other countries are subject to. As Brian Jacobsen, chief economist at Annex Wealth Management, said, "It's a sign of the times that markets would cheer 15% tariffs. A year ago, that level of tariffs would be shocking. Today, we breathe a sigh of relief." That, in essence, is the anchoring effect at play. Trump announces 'massive' trade deal with Japan. The country's exports to the U.S. will face a 15% tariff, Trump said. Japan's Prime Minister Shigeru Ishiba said auto tariffs on Tokyo will be lowered to 15% from the current 25% across countries. The U.S. and Indonesia agree on a trade framework. Imports into the U.S. from Indonesia will be set at 19%, while goods flowing from America to the Southeast Asian country will be tariff-free, according to a joint statement issued by the White House on Tuesday. Tariff suspension with China likely to be extended. The U.S. and China's 90-day tariff pause expires on Aug. 12. However, U.S. Treasury Secretary Scott Bessent said the U.S. will be "working out what is likely an extension." The S&P 500 ticks up to a fresh record. That's the index's 11th record close in 2025. On Tuesday, the Dow Jones Industrial Average also rose, but the Nasdaq Composite slipped. Japan's Nikkei 225 jumped over 3% on Wednesday, fueled by a surge in auto stocks. [PRO] Tailwinds from China's $167 billion mega-dam project. China has kicked off construction on the world's largest hydropower dam, and analysts expect suppliers of the project to receive a huge boost. Chinese and EU leaders are about to meet — but the U.S. is complicating things China and the European Union will hold a top-level meeting in Beijing on Thursday, while the U.S. is making their already tense relationship more complicated. Clashes over trade and economic policy, technological issues and defense and security have been commonplace between China and the EU — and tensions have recently been heating up.
Bloomberg
a minute ago
- Bloomberg
SAP CEO on Earnings, Trade, AI Demand
CC-Transcript 00:00I'm just reading through some analysts reaction and the word cautious and caution is coming through in terms of the analysts response to these earnings. What is behind that caution, the cautious commentary coming through from you and the team? Yeah, First of all, thanks for having me. Good morning, Tom. Look, I mean, when you take the macro uncertainty out and of course, currency headwinds, I mean, look at the underlying performance, which is growing by 28%. This is even an acceleration compared to Q1 by two percentage points. The backlog is now up to €18 billion, showing the resiliency of SAP. And even more important, when you look at innovation in AI, over half of the deals embedded AI showing the strong demand of our customers for business AI and yes, of course we see the macro uncertainty out there, we see the currency headwinds, but what we control is our own performance. And that was really, really good this quarter. Okay, so your own performance was strong. What is the extent, though, of that caution amongst your customers when it comes to the tariff uncertainty? What are you hearing from your clients and what extent to what extent they are slowing down maybe some of their orders? I mean, Tom, what we are seeing in a in a very few industries, I take the U.S. public sector take manufacturing. I mean, there are already customers who hit who got hit hard by tariffs. And obviously there we see some elongated sales cycles. I mean, they have tied our cost controls as they, you know, already feel the pressure out of the tariffs. And these are the moments where we have to, of course, convince even more with strong business cases. The good piece is, Tom, when you look at our half year pipeline that is actually very strong and the customers see actually our software AI as a solution to overcome those challenges. And we still just need to, of course, work more diligently with some of the customers who already got hit hard by tariffs. European stock futures up this morning on expectations that maybe Europe can emulate Japan and get a deal with the US. If Europe does not get a deal with the US, what will the impact be on SAP, do you think? I mean, the the good piece is when you look at SAP, we are doing business in over 100 countries in the world now. So we are having a resiliency just by, you know, the coverage of all of the geos. We are also growing 25 industries still. Of course, what is for us, very important, is predictable trade. And so we are, of course, also looking forward that also Europe can really cut a deal with the US because we need it. I mean, when the overall economy is going down, I mean, obviously no one is immune against that. That's why I'm still hoping that, you know, Europe can follow Japan and also, you know, agreeing to a deal with the United States. Yeah. And look, you obviously have have close contact with the German government. You are the most valuable company in Europe after all. What signals are you getting, Christian, from the German government around the likelihood of a deal between Europe and the US? I mean, from what I know, of course there are ongoing negotiations and they are negotiating also in good faith. I mean, they really want to come together and, you know, talking to each other is the first step. Now, the second step is that both sides are willing to compromise to find a deal. So I'm staying optimistic now that they gonna find a deal now in Q3, that would be important. I would say, you know, there could be the only winners on both sides of the ocean if they can find a deal and it gets with that spirit. Also, the German government is leaning in. 30%. Around 30% of your sales coming coming from the US, as that is the biggest single market for S & P. And you've talked about the currency pressures. The weaker dollar is a drag. Do you expect that and trying to be there and to show up in the results next year as well? Christian In 2026. I mean, it all depends how the currency, you know, will develop. I mean, of course, if it stays like that, of course we will gonna see a further currency impact. But we always guide at constant currency. I mean this is, you know, what we can control And Dow of course we expect an ongoing strong business. The currency is hard to influence. If it stays like that, obviously there will be, you know, further impact. But again, you know, currency, you know, fluctuates, you know, over the last five years a lot. And what really is for us, important that the underlying performance of ACP obviously stays too long. Yeah. Is there more you can do to mitigate the effects effects in terms of hedging? Yes. Yes, yes, yes. I mean, of course, we are doing we are hatching, obviously. And then, of course, second, what we also then, of course, are doing is, again, you know, across the geo, I mean, we are closing contracts in all parts of the world. We have huge multinationals. We can also close certain contracts in local countries. There is, of course, certain things what we can do. Again, Tom, for us, it's very important that pipeline is strong. We actually see strong execution so far in the year and that is of course, our main focus. And then that the currency of cost, our certain things, what we can mechanically do and we going to do that. Yeah. What is the high demand? How much of a catalyst as a driver will that demand for air services from IP B do you think, in 20, in 2026? I mean, Tom, given now that we already delivered 40 air agents, no matter if it's about financial close cash conversion, about better quotes, better pricing, understand better consumer trends or about supply chain resiliency to customers? Are we really leaning in? I mean, we are, as I said, 50% of the deals already, including I the adoption is going up, up, up and the customers. And that is for me very important. They see the productivity increases. You know, after applying as AP business they I and of course that now that we are delivering more and more on top of our I foundation and together with our new data offering business data cloud, I actually of course expect that we see a further surge in business. I also in 2026. Okay. A further surge in business in 2026. All that backlog. Before we let you go, Christine, the backlog of €18 billion, that's the support coming through. What does that backlog of orders look like by the end of 2025? Look, that really depends now on the second half of the year. I mean, of course, we said pipeline is strong and we have a really, really good pipeline coverage on the other side based as megawatt uncertainty. So it will now all depend on, you know, can we really execute on all of the pipeline? And so the backlog will further quo. To what extent really depends, Dan, on macro uncertainty. And of course, if execution stays strong, as in half year one, we confirmed our outlook, so we stay positive for the year.
Yahoo
28 minutes ago
- Yahoo
Clorox Earnings Preview: What to Expect
Oakland, California-based The Clorox Company (CLX) manufactures and markets consumer and professional products. It operates through Health and Wellness, Household, Lifestyle, and International segments. With a market cap of $15.6 billion, Clorox's portfolio consists of diverse brands sold in more than 100 countries and nearly every region of the world. The company is expected to release its Q4 results after the market closes on Thursday, Jul. 31. Ahead of the event, analysts expect CLX to report an EPS of $2.24, up an impressive 23.1% from $1.82 reported in the year-ago quarter. While the company has missed Street's bottom-line estimates once over the past four quarters, it has surpassed the projections on three other occasions. More News from Barchart Opendoor Stock Is Surging Higher in a Frenzied Retail Rally. How Should You Play OPEN Shares Here? Nvidia Stock Warning: This NVDA Challenger Just Scored a Major Customer Analysts Are Cutting Their Price Targets for UnitedHealth Stock Before Q2 Earnings. Is It Time to Ditch Shares? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For the full fiscal 2025, its EPS is expected to come in at $7.08, marking a solid 14.8% growth from $6.17 in fiscal 2024. But in fiscal 2026, its earnings are expected to plunge 8.6% year-over-year to $6.47 per share. CLX stock prices have dipped 2.4% over the past 52 weeks, notably underperforming the S&P 500 Index's ($SPX) 13.4% returns and the Consumer Staples Select Sector SPDR Fund's (XLP) 4.5% uptick during the same time frame. CLX stock prices dropped 2.4% in the trading session after the release of its disappointing Q3 results on May 5. Due to an unfavorable price mix, the company's organic sales dropped by 2% year-over-year. Further, its overall sales dropped 8.1% year-over-year to $1.7 billion due to divestitures of the VMS and Argentina businesses. This figure missed consensus estimates by a large margin. Moreover, its adjusted EPS plunged 15.2% year-over-year to $1.45, missing the consensus estimates by 7.6%, breaking its 10 quarters long streak of positive earnings surprises. CLX stock maintains a consensus 'Hold' rating overall, as analysts remain cautious about its prospects. Of the 18 analysts covering the stock, opinions include only one 'Strong Buy,' 13 'Holds,' and four 'Strong Sell' ratings. As of writing, the stock is trading slightly below its mean price target of $134.69. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
